Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Erythropoietin (EPO) Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Erythropoietin (EPO) Drugs Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Epoetin-alfa
      • 1.3.3 Darbepoetin-alfa
      • 1.3.4 Epoetin-beta
      • 1.3.5 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global Erythropoietin (EPO) Drugs Market Share by Application (2019-2025)
      • 1.4.2 Anemia
      • 1.4.3 Kidney Disorders
      • 1.4.4 Other
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Erythropoietin (EPO) Drugs Market Size
      • 2.1.1 Global Erythropoietin (EPO) Drugs Revenue 2014-2025
      • 2.1.2 Global Erythropoietin (EPO) Drugs Sales 2014-2025
    • 2.2 Erythropoietin (EPO) Drugs Growth Rate by Regions
      • 2.2.1 Global Erythropoietin (EPO) Drugs Sales by Regions 2014-2019
      • 2.2.2 Global Erythropoietin (EPO) Drugs Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Erythropoietin (EPO) Drugs Sales by Manufacturers
      • 3.1.1 Erythropoietin (EPO) Drugs Sales by Manufacturers 2014-2019
      • 3.1.2 Erythropoietin (EPO) Drugs Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Erythropoietin (EPO) Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Erythropoietin (EPO) Drugs Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Erythropoietin (EPO) Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.3 Erythropoietin (EPO) Drugs Price by Manufacturers
    • 3.4 Key Manufacturers Erythropoietin (EPO) Drugs Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Erythropoietin (EPO) Drugs Market
    • 3.6 Key Manufacturers Erythropoietin (EPO) Drugs Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Epoetin-alfa Sales and Revenue (2014-2019)
      • 4.1.2 Darbepoetin-alfa Sales and Revenue (2014-2019)
      • 4.1.3 Epoetin-beta Sales and Revenue (2014-2019)
      • 4.1.4 Others Sales and Revenue (2014-2019)
    • 4.2 Global Erythropoietin (EPO) Drugs Sales Market Share by Type
    • 4.3 Global Erythropoietin (EPO) Drugs Revenue Market Share by Type
    • 4.4 Erythropoietin (EPO) Drugs Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Erythropoietin (EPO) Drugs Sales by Application

    6 United States

    • 6.1 United States Erythropoietin (EPO) Drugs Breakdown Data by Company
    • 6.2 United States Erythropoietin (EPO) Drugs Breakdown Data by Type
    • 6.3 United States Erythropoietin (EPO) Drugs Breakdown Data by Application

    7 European Union

    • 7.1 European Union Erythropoietin (EPO) Drugs Breakdown Data by Company
    • 7.2 European Union Erythropoietin (EPO) Drugs Breakdown Data by Type
    • 7.3 European Union Erythropoietin (EPO) Drugs Breakdown Data by Application

    8 China

    • 8.1 China Erythropoietin (EPO) Drugs Breakdown Data by Company
    • 8.2 China Erythropoietin (EPO) Drugs Breakdown Data by Type
    • 8.3 China Erythropoietin (EPO) Drugs Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Erythropoietin (EPO) Drugs Breakdown Data by Company
    • 9.2 Rest of World Erythropoietin (EPO) Drugs Breakdown Data by Type
    • 9.3 Rest of World Erythropoietin (EPO) Drugs Breakdown Data by Application
    • 9.4 Rest of World Erythropoietin (EPO) Drugs Breakdown Data by Countries
      • 9.4.1 Rest of World Erythropoietin (EPO) Drugs Sales by Countries
      • 9.4.2 Rest of World Erythropoietin (EPO) Drugs Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Amgen
      • 10.1.1 Amgen Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Erythropoietin (EPO) Drugs
      • 10.1.4 Erythropoietin (EPO) Drugs Product Introduction
      • 10.1.5 Amgen Recent Development
    • 10.2 Johnson & Johnson
      • 10.2.1 Johnson & Johnson Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Erythropoietin (EPO) Drugs
      • 10.2.4 Erythropoietin (EPO) Drugs Product Introduction
      • 10.2.5 Johnson & Johnson Recent Development
    • 10.3 Roche
      • 10.3.1 Roche Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Erythropoietin (EPO) Drugs
      • 10.3.4 Erythropoietin (EPO) Drugs Product Introduction
      • 10.3.5 Roche Recent Development
    • 10.4 Galenica
      • 10.4.1 Galenica Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Erythropoietin (EPO) Drugs
      • 10.4.4 Erythropoietin (EPO) Drugs Product Introduction
      • 10.4.5 Galenica Recent Development
    • 10.5 Emcure
      • 10.5.1 Emcure Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Erythropoietin (EPO) Drugs
      • 10.5.4 Erythropoietin (EPO) Drugs Product Introduction
      • 10.5.5 Emcure Recent Development
    • 10.6 Kyowa Hakko Kirin
      • 10.6.1 Kyowa Hakko Kirin Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Erythropoietin (EPO) Drugs
      • 10.6.4 Erythropoietin (EPO) Drugs Product Introduction
      • 10.6.5 Kyowa Hakko Kirin Recent Development
    • 10.7 3SBio
      • 10.7.1 3SBio Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Erythropoietin (EPO) Drugs
      • 10.7.4 Erythropoietin (EPO) Drugs Product Introduction
      • 10.7.5 3SBio Recent Development
    • 10.8 Biocon
      • 10.8.1 Biocon Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Erythropoietin (EPO) Drugs
      • 10.8.4 Erythropoietin (EPO) Drugs Product Introduction
      • 10.8.5 Biocon Recent Development
    • 10.9 LG Life Sciences
      • 10.9.1 LG Life Sciences Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Erythropoietin (EPO) Drugs
      • 10.9.4 Erythropoietin (EPO) Drugs Product Introduction
      • 10.9.5 LG Life Sciences Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Erythropoietin (EPO) Drugs Sales Channels
      • 11.2.2 Erythropoietin (EPO) Drugs Distributors
    • 11.3 Erythropoietin (EPO) Drugs Customers

    12 Market Forecast

    • 12.1 Global Erythropoietin (EPO) Drugs Sales and Revenue Forecast 2019-2025
    • 12.2 Global Erythropoietin (EPO) Drugs Sales Forecast by Type
    • 12.3 Global Erythropoietin (EPO) Drugs Sales Forecast by Application
    • 12.4 Erythropoietin (EPO) Drugs Forecast by Regions
      • 12.4.1 Global Erythropoietin (EPO) Drugs Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Erythropoietin (EPO) Drugs Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      EPO is a naturally occurring hormone produced by cells in the kidneys that regulate the production of red blood cells in bone marrow.
      Increasing incidence of chronic diseases such as end-stage renal diseases, cancer, and HIV is expected to accelerate demand for EPO-stimulating agents as these diseases may cause anemia. To curb rising incidence of anemia, demand for erythropoietin drugs is expected to increase over the coming years.
      In 2019, the market size of Erythropoietin (EPO) Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Erythropoietin (EPO) Drugs.

      This report studies the global market size of Erythropoietin (EPO) Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Erythropoietin (EPO) Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Amgen
      Johnson & Johnson
      Roche
      Galenica
      Emcure
      Kyowa Hakko Kirin
      3SBio
      Biocon
      LG Life Sciences

      Market Segment by Product Type
      Epoetin-alfa
      Darbepoetin-alfa
      Epoetin-beta
      Others

      Market Segment by Application
      Anemia
      Kidney Disorders
      Other

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Erythropoietin (EPO) Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Erythropoietin (EPO) Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Erythropoietin (EPO) Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now